Latest Development Programs News

Tamboran Resources Corporation has initiated a significant equity raise totaling approximately US$198 million to fund expanded drilling and development activities in the Beetaloo Basin. The capital raise includes a registered underwritten public offering and a pro rata entitlement offer, representing a 25% increase in shares on issue.

Lumos Diagnostics has entered a three-year contract manufacturing agreement with Micro-Pak to produce the Mold Analyzer system, marking a transition from development to commercial-scale manufacturing with an initial US$250,000 purchase order.

BluGlass Limited (ASX: BLG) has entered a A$1.3 million strategic collaboration with a Fortune 500 global data storage company to advance photonics research using its proprietary visible laser technology.

Tamboran Resources reports robust and stable gas production from its Shenandoah South 6H well, marking a key milestone ahead of planned gas sales in late 2026.

Following ASIC's final inquiry report, ASX unveils a comprehensive transformation plan focusing on governance, leadership, and risk management, alongside a significant capital charge.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.

Electro Optic Systems secures two significant US contracts worth US$12 million for advanced Remote Weapon Systems, while progressing a conditional US$80 million Korean High Energy Laser contract with potential manufacturing shifts.

Brookside Energy has commenced site preparation for a two-well development pad in the SWISH Area of Interest, with drilling set to begin in May 2026 targeting key formations in the Anadarko Basin.

Pioneer Minerals has secured membership in the US Defense Industrial Base Consortium, positioning its Idaho-based North Pine tungsten project at the heart of critical mineral supply chain initiatives.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

BPH Global is expanding its seaweed biomass research to develop renewable biofuels like biohydrogen and biocrude, aiming to carve out a sustainable alternative to fossil fuels in energy and transport sectors.